La Corte Superior de Justicia de Piura realizó la ceremonia de clausura del Curso Gratuito para Orientadoras Judiciales 2025, dirigido a treinta mujeres líderes de la región, como parte de su ...

Curso dirigido a profesionales de la Ingeniería Civil, Vial, Hidráulica, Construcciones y disciplinas conexas, técnicos en especialidades vinculadas con ríos y canales, estudiantes avanzados de esas ...

The RPSC has announced the RAS mains result 2025, with 2,461 candidates declared successful. The mains exam was held on June 17 and 18, 2025, across multiple centres in Rajasthan in two shifts daily.

Con el objetivo de capacitar a mujeres líderes en temas de acceso a la justicia y promover la reducción de conflictos en la comunidad, laCorte Superior de Justicia de Piura inauguró el Curso Gratuito ...

The top job in Pakistani higher education is, by design, a temporary one. The chairperson of the Higher Education Commission (HEC) now gets a mere two years — instead of four — to steward the ...

Bain Capital agreed to sell its data centers in China to Shenzhen Dongyangguang Industry Co. in a transaction valued at about $4 billion. Shenzhen Dongyangguang, the parent of Shanghai-listed ...

Marking a historic milestone, the U.S. Coast Guard announced Monday the combined interdiction of more than 76,140 pounds of illicit narcotics. The quantity of drugs offloaded at Port Everglades is the ...

The federal government has appointed Secretary Education Nadeem Mahbub as the acting chairman of Higher Education Commission since Dr Mukhtar Ahmed’s term has ended. The Ministry of Education has ...

A local court in Islamabad ordered the reinstatement of Dr Ziaul Qayyum as Executive Director of the Higher Education Commission (HEC). However, despite the court's orders, the HEC administration did ...

ISLAMABAD – The court has reinstated Professor Dr. Zia-ul-Qayyum as the Executive Director of the Higher Education Commission (HEC) after suspending his termination orders issued earlier this year.

Revolution Medicines has secured a potential funding infusion of up to $2 billion from Royalty Pharma in return for a slice of the profits if Revolution’s lead cancer drug makes it to market.